Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Keil, Germany Clinical Trials

A listing of Keil, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

Phase 1 Trial of MSC2490484A an Inhibitor of a DNA-dependent Protein Kinase in Combination With Radiotherapy

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Phase

0.0 miles

Learn More »

Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).

Phase

1.43 miles

Learn More »

Study of REGN2810 and REGN1979 in Patients With Lymphoma

This is an open-label, multicenter, dose escalation study of REGN2810 and REGN1979 in patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on how an individual patient responds to treatment. The follow-up period will be 6 months for all patients.

Phase

1.43 miles

Learn More »

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

CD19 is present on B-cells from earliest recognizable B-lineage cells during development to B-cell blasts and is lost only upon maturation to plasma cells. Expression of CD19 on B-cells at various development stages makes it an ideal target to treat B-cell associated malignancies.The rationale for the use of AFM11 is ...

Phase

1.43 miles

Learn More »

Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes

reduce of immunsupression or introduce tolerance with so called TAIZ-monocytes in renal transplant patients

Phase

1.43 miles

Learn More »

Study of Single Agent CJM112 and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma.

Phase

1.43 miles

Learn More »

Clinical Study to Evaluate the Pharmacokinetics Safety Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects

To investigate the pharmacokinetics of BAY1101042 in subjects with mild to severe renal impairment, stratified according to estimated glomerular filtration rate (eGFR) determined 2-10 days prior to dosing, and age-, weight- and gender- matched healthy subjects and to assess the safety, tolerability, and pharmacodynamics of BAY1101042 after a single oral ...

Phase

1.43 miles

Learn More »

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

This is an open label, randomized, multi-centre study in postmenopausal women with primary ER+ HER2- breast cancer. Patients will be randomised to an oral dose of 250 mg bd AZD9496 or 500mg fulvestrant i.m. administered on one occasion. Patients diagnosed with primary breast cancer who are scheduled for surgery with ...

Phase

1.43 miles

Learn More »